Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc. (MTNB): 1 pipeline candidate · ~5 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
4.7 months
D/E 0.94 · 0% dilution
Lead: Phase 3
1 candidate
N/A
N/A
A transparent, data-derived signal for Matinas BioPharma Holdings, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$4.8M
Cash
$2.4M
Quarterly Burn
$1.6M
Runway
4.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| mat2203 | Phase 3 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
27
Total value held
$182K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 80,220 | $40K |
| geode capital management, llc | 65,170 | $33K |
| citadel advisors llc | 51,698 | $26K |
| blackrock, inc. | 49,650 | $25K |
| renaissance technologies llc | 28,570 | $14K |
| xtx topco ltd | 20,706 | $10K |
| vanguard fiduciary trust co | 18,277 | $9K |
| state street corp | 15,322 | $8K |
| susquehanna international group, llp | 14,328 | $7K |
| sargent investment group, llc | 12,720 | $6K |
Showing top 10 of 27 institutional holders of Matinas BioPharma Holdings, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Matinas BioPharma Holdings, Inc.'s pipeline?
Matinas BioPharma Holdings, Inc. (MTNB) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Matinas BioPharma Holdings, Inc.'s lead drug candidate?
Matinas BioPharma Holdings, Inc.'s most advanced tracked candidate is mat2203 (Phase 3) for invasive aspergillosis in patients with limited treatment options.
What is Matinas BioPharma Holdings, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Matinas BioPharma Holdings, Inc. has approximately 4.7 months of cash runway.
What is Matinas BioPharma Holdings, Inc.'s market capitalization?
Matinas BioPharma Holdings, Inc.'s market capitalization is approximately $4.8M.
Who is the CEO of Matinas BioPharma Holdings, Inc.?
Mr. Jerome D. Jabbour J.D. is the chief executive officer of Matinas BioPharma Holdings, Inc. (MTNB).
Get the full picture on Matinas BioPharma Holdings, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.